TR201900778T4 - İmmünojenik bileşim. - Google Patents
İmmünojenik bileşim. Download PDFInfo
- Publication number
- TR201900778T4 TR201900778T4 TR2019/00778T TR201900778T TR201900778T4 TR 201900778 T4 TR201900778 T4 TR 201900778T4 TR 2019/00778 T TR2019/00778 T TR 2019/00778T TR 201900778 T TR201900778 T TR 201900778T TR 201900778 T4 TR201900778 T4 TR 201900778T4
- Authority
- TR
- Turkey
- Prior art keywords
- protein
- saccharide
- saccharides
- meningitidis
- polysaccharides
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 4
- 150000004676 glycans Chemical class 0.000 abstract 4
- 229920001282 polysaccharide Polymers 0.000 abstract 4
- 239000005017 polysaccharide Substances 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 abstract 2
- 241000588650 Neisseria meningitidis Species 0.000 abstract 2
- 230000021615 conjugation Effects 0.000 abstract 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN281MU2012 | 2012-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201900778T4 true TR201900778T4 (tr) | 2019-02-21 |
Family
ID=54259032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/00778T TR201900778T4 (tr) | 2012-01-30 | 2013-01-29 | İmmünojenik bileşim. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9198977B2 (enExample) |
| EP (1) | EP2809349B1 (enExample) |
| JP (1) | JP6042455B2 (enExample) |
| KR (1) | KR101897317B1 (enExample) |
| CN (1) | CN104302315B (enExample) |
| BR (1) | BR112014018815B1 (enExample) |
| CA (1) | CA2863178C (enExample) |
| DK (1) | DK2809349T3 (enExample) |
| ES (1) | ES2707294T3 (enExample) |
| HU (1) | HUE040914T4 (enExample) |
| MX (1) | MX354103B (enExample) |
| PT (1) | PT2809349T (enExample) |
| RU (1) | RU2634405C2 (enExample) |
| SG (1) | SG11201404447WA (enExample) |
| SI (1) | SI2809349T1 (enExample) |
| TR (1) | TR201900778T4 (enExample) |
| WO (1) | WO2013114268A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110072A1 (es) * | 2005-06-27 | 2011-02-04 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
| WO2014080423A2 (en) * | 2012-11-21 | 2014-05-30 | Serum Institute Of India Ltd. | Production of high yields of bacterial polysaccharides |
| KR102447303B1 (ko) * | 2013-08-24 | 2022-09-23 | 브하라트 바이오테크 인터내셔날 리미티드 | 박테리아성 백신 및 그의 제조방법 |
| EP2921856B1 (en) | 2014-03-18 | 2016-09-14 | Serum Institute Of India Private Limited | A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines |
| EA201792470A1 (ru) * | 2015-06-08 | 2018-10-31 | Серум Инститьют Оф Индия Прайват Лтд. | Способы улучшения адсорбции полисахарид-белковых конъюгатов и полученная из них композиция поливалентной вакцины |
| WO2017006349A1 (en) * | 2015-07-04 | 2017-01-12 | Bharat Biotech International Limited | Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides |
| JP2019508468A (ja) * | 2016-03-15 | 2019-03-28 | エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドＭｓｄ Ｗｅｌｌｃｏｍｅ Ｔｒｕｓｔ Ｈｉｌｌｅｍａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｐｖｔ．Ｌｔｄ． | 新規の多糖体−タンパク質コンジュゲート及びそれを得る方法 |
| CN106110316A (zh) * | 2016-06-27 | 2016-11-16 | 北京智飞绿竹生物制药有限公司 | 一种肺炎球菌结合物组合疫苗的制备方法 |
| BR112019003992A2 (pt) * | 2016-09-02 | 2019-05-28 | Sanofi Pasteur Inc | vacina contra neisseria meningitidis |
| CN106397537B (zh) * | 2016-10-13 | 2020-01-07 | 李红臣 | 一种高效快速的多糖蛋白结合疫苗纯化分析方法 |
| US11739356B2 (en) | 2017-05-05 | 2023-08-29 | Serum Institute Of India Private Limited | Method for removal of impurities from bacterial capsular polysaccharide based preparations |
| JP2020525495A (ja) * | 2017-06-27 | 2020-08-27 | エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドＭｓｄ Ｗｅｌｌｃｏｍｅ Ｔｒｕｓｔ Ｈｉｌｌｅｍａｎ Ｌａｂｏｒａｔｏｒｉｅｓ Ｐｖｔ．Ｌｔｄ． | 新規の多価多糖類・タンパク質のコンジュゲートワクチン組成物及びその製剤 |
| US20200353064A1 (en) * | 2018-01-29 | 2020-11-12 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Novel meningococcal vaccine composition and process thereof |
| WO2019198096A1 (en) * | 2018-04-11 | 2019-10-17 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Tetravalent meningococcal vaccine composition and process to prepare thereof |
| JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
| WO2021059181A1 (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| WO2022035816A1 (en) | 2020-08-10 | 2022-02-17 | Inventprise, Llc | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| CN118078981A (zh) * | 2024-04-26 | 2024-05-28 | 成都康华生物制品股份有限公司 | 一种基于双蛋白载体的五价脑膜炎球菌多糖结合疫苗的制备方法及其产品 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2763244B1 (fr) * | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| CZ20024224A3 (cs) * | 2000-06-29 | 2003-05-14 | Glaxosmithkline Biologicals S. A. | Farmaceutický prostředek |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| GB0130215D0 (en) * | 2001-12-18 | 2002-02-06 | Glaxosmithkline Biolog Sa | Vaccine |
| NZ546430A (en) * | 2003-10-02 | 2009-04-30 | Novartis Vaccines & Diagnostic | Liquid vaccines for multiple meningococcal serogroups |
| PE20110072A1 (es) * | 2005-06-27 | 2011-02-04 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| JP5135220B2 (ja) * | 2005-09-01 | 2013-02-06 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 血清群ｃ髄膜炎菌を含む複数ワクチン接種 |
| KR101515078B1 (ko) * | 2005-12-22 | 2015-04-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| GB0703369D0 (en) * | 2007-02-21 | 2007-03-28 | Health Prot Agency | Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines |
| CA2836153C (en) * | 2009-12-17 | 2016-06-21 | Fina Biosolutions, Llc | Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines |
| RU2014151567A (ru) * | 2012-05-22 | 2016-07-10 | Новартис Аг | Конъюгат менингококка серогруппы х |
-
2013
- 2013-01-29 MX MX2014009250A patent/MX354103B/es active IP Right Grant
- 2013-01-29 JP JP2014555364A patent/JP6042455B2/ja active Active
- 2013-01-29 KR KR1020147024348A patent/KR101897317B1/ko active Active
- 2013-01-29 RU RU2014134288A patent/RU2634405C2/ru active
- 2013-01-29 PT PT13743463T patent/PT2809349T/pt unknown
- 2013-01-29 BR BR112014018815-7A patent/BR112014018815B1/pt active IP Right Grant
- 2013-01-29 WO PCT/IB2013/050739 patent/WO2013114268A1/en not_active Ceased
- 2013-01-29 DK DK13743463.5T patent/DK2809349T3/da active
- 2013-01-29 SG SG11201404447WA patent/SG11201404447WA/en unknown
- 2013-01-29 US US14/375,385 patent/US9198977B2/en active Active
- 2013-01-29 CA CA2863178A patent/CA2863178C/en active Active
- 2013-01-29 SI SI201331329T patent/SI2809349T1/sl unknown
- 2013-01-29 TR TR2019/00778T patent/TR201900778T4/tr unknown
- 2013-01-29 HU HUE13743463A patent/HUE040914T4/hu unknown
- 2013-01-29 CN CN201380017781.9A patent/CN104302315B/zh active Active
- 2013-01-29 EP EP13743463.5A patent/EP2809349B1/en active Active
- 2013-01-29 ES ES13743463T patent/ES2707294T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE040914T4 (hu) | 2019-05-28 |
| MX2014009250A (es) | 2015-03-19 |
| KR101897317B1 (ko) | 2018-09-11 |
| CA2863178A1 (en) | 2013-08-08 |
| BR112014018815B1 (pt) | 2022-07-12 |
| KR20140123553A (ko) | 2014-10-22 |
| CN104302315B (zh) | 2018-02-06 |
| JP2015509111A (ja) | 2015-03-26 |
| RU2634405C2 (ru) | 2017-10-26 |
| US20140377302A1 (en) | 2014-12-25 |
| SI2809349T1 (sl) | 2019-03-29 |
| JP6042455B2 (ja) | 2016-12-14 |
| PT2809349T (pt) | 2019-02-01 |
| ES2707294T3 (es) | 2019-04-03 |
| EP2809349B1 (en) | 2018-12-19 |
| WO2013114268A1 (en) | 2013-08-08 |
| BR112014018815A8 (pt) | 2017-07-11 |
| BR112014018815A2 (enExample) | 2017-06-20 |
| RU2014134288A (ru) | 2016-03-20 |
| MX354103B (es) | 2018-02-13 |
| EP2809349A4 (en) | 2015-08-26 |
| CN104302315A (zh) | 2015-01-21 |
| US9198977B2 (en) | 2015-12-01 |
| DK2809349T3 (da) | 2019-02-18 |
| CA2863178C (en) | 2021-04-06 |
| SG11201404447WA (en) | 2014-08-28 |
| EP2809349A1 (en) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201900778T4 (tr) | İmmünojenik bileşim. | |
| MX2025002072A (es) | Un conjugado de un agente citotoxico y una molecula de union a celulas con enlazadores ramificados | |
| MY148110A (en) | Immunogenic composition | |
| BR112012019757B8 (pt) | Composição imunogênica, e, uso de uma mistura de conjugado de polissacarídeo-proteína multivalente | |
| PH12018501517A1 (en) | Neisseria meningitidis compositions and methods thereof | |
| EP2408470A4 (en) | SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE | |
| JP2014218516A5 (enExample) | ||
| Danieli et al. | Synthesis of Staphylococcus aureus type 5 capsular polysaccharide repeating unit using novel L-FucNAc and D-FucNAc synthons and immunochemical evaluation | |
| TR201907313T4 (tr) | İki PEG zinciri içeren PEG türevleri. | |
| NZ739788A (en) | Phthalocyanine dye conjugates and their storage | |
| AR060187A1 (es) | Composicion inmunogenica | |
| RU2009130447A (ru) | Модифицированные сахариды | |
| CL2016000566A1 (es) | Método para para preparar una composición inmunogénica multivalente que comprende 13 conjugados de un serotipo diferente de streptococcus pneumoniae, donde cada uno de los conjugados contiene un polisacárido capsular diferente conjugado a la proteína portadora crm197. div. sol. madre n° 200600802 e hija cl 201702206. | |
| PE20110065A1 (es) | Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8 | |
| JP2015518845A5 (enExample) | ||
| RU2014151567A (ru) | Конъюгат менингококка серогруппы х | |
| BRPI0206672B8 (pt) | composição imunológica, vacina conjugada tetravalente e vacina meningocócica multivalente | |
| HRP20240433T1 (hr) | Cjepivo protiv neisseria meningitidis | |
| IN2014DN09791A (enExample) | ||
| BR112019001995A2 (pt) | composição de conjugado de polissacarídeo pneumocócico multivalente ? proteína | |
| IN2012MN02262A (enExample) | ||
| HRP20090607T8 (en) | Combined meningococcal conjugates with common carrier protein | |
| JP2015509111A5 (enExample) | ||
| RU2007102016A (ru) | Пространственный анализ конъюгатов сахаридов с помощью gpc и sec-mals | |
| BRPI0411875A (pt) | método de imunização contra os sorogrupos a e c de neisseria meningitidis |